Abstract
There is increasing evidence that sodium glucose cotransporter 2 (SGLT2) inhibitors have renoprotective effects, as demonstrated by the renal analyses from clinical trials including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME), CANagliflozin Treatment And Trial Analysis versus SUlphonylurea (CANTATA-SU), and the dapagliflozin renal study. The potential mechanisms responsible are likely multifactorial, and direct renovascular and hemodynamic effects are postulated to play a central role. This report reviews the renal outcomes data from key SGLT2 inhibitor clinical trials, discusses the hypotheses for SGLT2 inhibitor-associated renoprotection, and considers the main renal safety issues associated with SGLT2 inhibitor treatment.
Citations
May 21, 2017·The American Journal of Medicine·Son V Pham, Robert Chilton
May 21, 2017·The American Journal of Medicine·Bart Staels
Jul 19, 2018·American Journal of Physiology. Renal Physiology·K Melissa HallowDavid W Boulton
Jan 10, 2018·Circulation·Jorge Plutzky, George Bakris
Nov 20, 2018·Postgraduate Medicine·Michael S KellyIvan Portillo
May 16, 2019·CPT: Pharmacometrics & Systems Pharmacology·Gabriel HelmlingerRobert C Penland
Aug 25, 2019·Advances in Therapy·Yehuda Handelsman
Aug 14, 2019·Diabetes, Obesity & Metabolism·Robert J Chilton
Sep 24, 2020·ESC Heart Failure·Rafael de la EspriellaJulio Núñez
Mar 7, 2020·Diabetes/metabolism Research and Reviews·Xiaodan ZhangWangen Li
Nov 28, 2018·Clinical and Experimental Nephrology·Satoru Kuriyama
Jun 28, 2018·Drugs·James E Frampton
Feb 17, 2019·Archives of Pharmacal Research·Sungmi ParkIn-Kyu Lee
Oct 30, 2020·European Endocrinology·Sanjay KalraAmit Kumar
Aug 19, 2021·Diabetes, Obesity & Metabolism·Temitope OlufadeAidar R Gosmanov
Oct 30, 2021·Journal of Cellular Physiology·Sreenithya Ravindran, Shankar Munusamy
Apr 3, 2019·Kidney & Blood Pressure Research·Chang ChuBerthold Hocher
Jul 11, 2019·Kidney & Blood Pressure Research·Satoru Kuriyama